S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 15.85 USD 0.38% Market Closed
Market Cap: 195.9m USD
Have any thoughts about
SWK Holdings Corp?
Write Note

SWK Holdings Corp
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SWK Holdings Corp
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
S
SWK Holdings Corp
NASDAQ:SWKH
Additional Paid In Capital
$4.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
LM Funding America Inc
NASDAQ:LMFA
Additional Paid In Capital
$97.8m
CAGR 3-Years
35%
CAGR 5-Years
41%
CAGR 10-Years
N/A
A-Mark Precious Metals Inc
NASDAQ:AMRK
Additional Paid In Capital
$172.4m
CAGR 3-Years
4%
CAGR 5-Years
45%
CAGR 10-Years
23%
FlexShopper Inc
NASDAQ:FPAY
Additional Paid In Capital
$42.8m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
11%
California First Leasing Corp
OTC:CFNB
Additional Paid In Capital
$1.6m
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
S
Standard Premium Finance Holdings Inc
OTC:SPFX
Additional Paid In Capital
$3.4m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SWK Holdings Corp
Glance View

Market Cap
194.4m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
18.11 USD
Undervaluation 12%
Intrinsic Value
Price
S

See Also

What is SWK Holdings Corp's Additional Paid In Capital?
Additional Paid In Capital
4.4B USD

Based on the financial report for Sep 30, 2024, SWK Holdings Corp's Additional Paid In Capital amounts to 4.4B USD.

What is SWK Holdings Corp's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
0%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top